Improved method for quantitative determination in serum of alkaline phosphatase of skeletal origin.
In this quantitative method for detection of skeletal alkaline phosphatase (EC 3.1.3.1) activity in human serum, intestinal and placental alkaline phosphatase activities are recognized by their susceptibility to inhibition by L-phenylalanine, and skeletal and hepatic alkaline phosphatases are distinguished by their different sensitivities to inactivation by heat. Alkaline phosphatase isoenzymes prepared from organ sources may behave differently from the corresponding isoenzymes in serum. Our procedure allows us to include organ-derived internal standards of skeletal, intestinal, and biliary alkaline phosphatase to minimize between-assay variation. In preliminary applications, we have found that (a) total serum alkaline phosphatase activity is extremely variable in post-menopausal osteoporotic subjects and is not a reliable index of skeletal alkaline phosphatase activity; (b) seven osteoporotic patients responding to therapy with sodium fluoride with increased bone formation showed increased skeletal alkaline phosphatase activity in their serum as compared with age-matched controls (p less than 0.005); and (c) 10 post-menopausal osteoporotic patients responding to therapy with stanozolol with increased total body calcium showed an increase in circulating skeletal alkaline phosphatase activity (p less than 0.001).
D000469:Alkaline Phosphatase / Q000097:blood*; D001842:Bone and Bones / Q000201:enzymology*; D005260:Female; D006358:Hot Temperature; D006801:Humans; D007422:Intestines / Q000201:enzymology; D007527:Isoenzymes / Q000097:blood*; D008099:Liver / Q000201:enzymology; D008593:Menopause; D008875:Middle Aged; D010024:Osteoporosis / Q000188:drug therapy / Q000201:enzymology*; D010649:Phenylalanine / Q000494:pharmacology; D010920:Placenta / Q000201:enzymology; D012969:Sodium Fluoride / Q000627:therapeutic use
D007527:Isoenzymes; D010649:Phenylalanine; D012969:Sodium Fluoride; D000469:Alkaline Phosphatase